

# Suspected Child Sexual Abuse

Harley Goldberg, DO, Eric M. Wall, MD, MPH, and Kate Commerford, PhD

Portland, Oregon

**D**R HARLEY GOLDBERG (*Third-Year Resident, Family Medicine*): The patient is a 13-year-old girl, whose care began with a family physician in an outlying community. She was initially seen by this physician in November of 1987 with complaints of 5 weeks of fatigue, intermittent fever, and chills, which were sufficient to keep her out of school. She was treated at that time with amoxicillin. She was seen again in February of 1988 with myalgias, some sinus drainage, and fatigue. She again had missed school for several weeks. A diagnosis of a possible viral syndrome was made and a second course of amoxicillin was prescribed. On February 19 the patient was given a home tutor to help her catch up from prolonged school absences for the same complaints. Three days later, her records reported a negative Monospot and moderate lymphadenopathy, and she was given a short tapering course of prednisone. On February 29 she returned to her physician with essentially the same complaints. On March 7 the severity of these symptoms seemed to be increasing with added problems of nausea and dizziness. The patient and family felt that there was a physical illness involved for which a more thorough investigation was required. Results of a chemistry panel, thyroid function tests, and a complete blood count were all normal. In April these same complaints were again reported, and the family physician entertained the possibility of endogenous depression. Antidepressants were offered and refused.

On April 15 the patient was referred to the Oregon Health Sciences University (OHSU) Pediatric Outpatient Clinic. A fairly extensive history revealed that she had no

pleasurable activities and spent most of her time watching television. She was not seeing her friends, though she occasionally talked with them on the telephone. She denied any other stresses, sibling rivalries, or family difficulties as well as any sexual contact. She said that she was attracted to boys but had no boyfriends. She claimed that when she was healthy, she was a good student, getting A's and B's, and that she basically felt comfortable with herself. The remainder of the examination was unremarkable. The assessment at this time was an endogenous depression. Recommendations included establishing rapport with the patient and bringing the entire family back for follow-up. Follow-up never occurred. The patient returned to the care of her private family physician.

In early June she complained of sweats and chills, occasional vomiting, shortness of breath, drowsiness, fatigue, and intermittent nasal congestion. On August 1 the father called the family physician saying that his daughter was "close to her deathbed," groaning, crying, refusing to eat. At that point, referral was made to OHSU Department of Family Medicine, and contact was made with the attending physician on the inpatient service, Dr Eric Wall.

**DR ERIC M. WALL** (*Associate Professor, Department of Family Medicine*): The family physician I spoke with was obviously very frustrated and requested hospital admission for a multidisciplinary assessment. The physician had approached the family with a diagnosis of depression and felt that the father in particular was resistant to a psychiatric label for the child's problem. He incidentally added that he had received a confidential letter, in April, from an aunt of the patient who said that when she—the aunt—was a teenager, she had been sexually abused by the father of the patient. The contents of this letter were not revealed at the time of the patient's pediatric outpatient visit. I asked whether the physician felt there was any suggestion that the patient had been sexually abused, and he admitted that this was a strong diagnostic possibility.

Submitted, revised, February 28, 1990.

From the Department of Family Medicine, Oregon Health Sciences University, Portland, Oregon. At the time this grand rounds was conducted, Dr Goldberg was a resident in the Department of Family Medicine at the Oregon Health Sciences University. Requests for reprints should be addressed to Eric M. Wall, MD, MPH, Department of Family Medicine, Oregon Health Sciences University, 3181 SW Sam Jackson Park Rd, Portland, OR 97201.



After consulting with a number of colleagues both within and outside our department, I recommended that if the physician strongly suspected sexual abuse, he should contact the Children's Services Division (CSD) in the county in which the family was living and at least explore any other potential avenues for evaluating the child. He called me back several days later and said that after exploring these options, CSD felt that there was not enough to go on to evaluate this child's situation. In fact, I later learned CSD had carried out an independent investigation of this child prior to this time. He again requested our help here in trying to sort out the problem with the patient. As there was no other means of access to her for a comprehensive evaluation, she was seen in the Family Practice Center by one of the faculty. That physician also felt that the child's complaints warranted inpatient investigation.

**DR GOLDBERG:** The patient's past medical history was unremarkable; she had no known allergies, nor was she taking any ongoing medications. Her family history involved some maternal family hypertension, obesity, and diabetes. The father had previously been hospitalized for pancreatitis and was told that he had adult-onset diabetes. The cause of the pancreatitis was unknown, according to the father. Menarche had started for the patient at 12 years of age (1½ years earlier), and she reported a regular menstrual cycle every 28 days lasting 3 to 4 days. She denied sexual activity of any kind.

The physical examination at admission revealed a pale, listless child moaning intermittently and crying that she was unable to move. One could, however, move her limbs, and she was able to stand and walk after considerable encouragement. Other than mild anterior cervical lymphadenopathy, the remainder of the physical examination was unremarkable. A gynecologic examination was not performed at admission, in view of the anticipated examination with Dr Mary Steinberg, the late hour, and the available male examiner. Her laboratory tests included a complete blood count, sedimentation rate, and chemistry profile, the results of which were normal.

As the differential diagnosis of biomedical illness became quickly exhausted, consultations were obtained with Dr Kate Commerford, from our own department; Dr David Holladay from the Department of Child Psychiatry; and Dr Mary Steinberg from the Department of Pediatrics, who in our institution is most experienced in the evaluation of suspected child sexual abuse. The course is summarized by the evaluations of each of these individuals, and I would like to ask each of them to present his or her perspective at this time.

**DR KATE COMMERFORD** (*Psychologist, Family Medicine*): My initial contact with the patient was on the first morning of her admission. She was lying in bed, pale and lethargic as has been described. She was very difficult

to interview, appearing to be wary of my questions and guarded in her answers. The patient completely denied any family or personal problems. She was unable to be specific about her interests or daily activities. She said that she liked to do outdoor things but was unable to describe what these were. She was unable to talk about specific activities of her life either before or since the onset of her illness. She had been out of school since November, so she had been mostly housebound. She described herself as honest, friendly, outgoing, and active.

In an effort to gather additional information about the patient and her family, a genogram was constructed (Figure 1). The identified patient has one male sibling 3 years younger than she. The patient's parents married in 1970, had a brief separation in 1971, and have continued to be married to this day. The mother's only health problem is hypertension. Although the mother's father is now sober, she grew up in an alcoholic family. The mother supports the family by working full time as a receptionist in a health facility.

The patient's father is the second of five children. He is a former Marine who is obese, weighing 270 pounds, and has adult-onset diabetes mellitus and a history of pancreatitis. His father died in 1984 of bone and other cancers, and his mother has a metastatic cancer. The father is not employed and has not been working for at least as long as the patient has been out of school. The father formally worked cutting wood, and his explanation for not working anymore was that "the truck broke." The father and mother both denied alcohol use. The mother and two children are Catholic; the father is not but attends some Catholic functions with them. The younger brother of the patient was described as hyperactive, though this could not be confirmed.


One thing that came up during the interview was that the patient would wake up at 5 AM to do her hair. While trying to determine whether this early morning awakening might be associated with depression (it was not), it was discovered that the family's sleeping arrangements were a bit unusual. The patient's father sleeps with her brother in the parents' bed, the mother sleeps downstairs in the son's room, and the patient is also downstairs in her own room. The explanation given was that the father snores and would otherwise keep the mother from sleeping. The parents also said that the son did not like to sleep alone.

When asked whether they had ever had those sleeping arrangements with the patient, both parents denied that she ever slept with her father. During the interview, the father did most of the talking. I felt that it was important to specifically ask whether either of the parents thought that the patient had been sexually abused. Both denied it, as did the patient when she was asked with neither parent present. The mother's response was that she did not think

Continued on page 527



Continued from page 524



that the father had abused the daughter because she "trusted" both of them.

The patient scored 6 on the Beck Children's Depression Inventory with 19 and above indicating depression in children. She clearly denied any symptoms that would go along with depression. The Minnesota Multiphasic Personality Inventory (MMPI) was also administered, and the adolescent norms were employed in scoring. This administration of the MMPI appeared to be valid, with results indicating someone who is very defensive. One of the most significant aspects of this patient's profile is the presence of a "conversion V." An individual with a "conversion V" is thought to be converting personally distressing problems into more socially acceptable ones. In other words, the patient's results suggest psychological problems are being converted into somatic complaints. Also of importance in the MMPI results is the lack of elevation on scales 6, 7, 8, and 9 (paranoia, psychasthenia,

and hypomania), which are typically quite elevated for adolescents. These scales contain items that acknowledge the confusion, anxiety, hypersensitivity, personal discomfort, and fear of social exposure that are typical of the adolescent period. The patient's scores on these scales were quite low and contribute to the interpretation of defensiveness on the MMPI.

DR DAVID HOLLADAY (*Third-Year Resident in Child Psychiatry*): When we went to interview the patient, we found her lying on the bed engaged in a lively sort of discussion that quickly changed after we introduced ourselves. She immediately looked quite ill, and it appeared she was trying to show us how sick she was. What was most remarkable was her denial of any and all problems. She was not very pleased to talk with us, although she was cooperative throughout the interview. We looked for obvious evidence of psychosis or major depression, which was not present. She was able to laugh spontaneously,



and her thoughts were clear and coherent throughout the interview.

DR COMMERFORD: Dr Wall mentioned that an aunt had written one of the patient's physicians and reported that she (the aunt) had been sexually abused by the patient's father, who is approximately 5 years older than she. She stated in the letter that she and her sister had been abused by the patient's father for 4 to 5 years during their adolescence.

DR GOLDBERG: Possible sexual abuse continued to be an issue for all who cared for this patient. For that reason we asked Dr Mary Steinberg of the Department of Pediatrics to evaluate the child.

## DIAGNOSTIC APPROACHES IN CASES OF SUSPECTED CHILD SEXUAL ABUSE

DR MARY STEINBERG (*Assistant Professor, Department of Pediatrics*): I am frequently asked to do examinations on children for whom there are concerns of sexual abuse. Many of the children I see are very young. Unfortunately, many reported sex abuse cases are of young children. In the physical examination of young girls, it is often easier to identify signs of molestation. There are some significant differences in the genitalia of prepubertal and postpubertal girls. In young girls the labia majora tend to be much thicker and overlie the introitus more. The clitoris is fairly prominent, but the labia minora are usually very small and attenuated. The urethras generally appear small. The hymenal tissue is generally annular, circumferential, or horseshoe shaped and surrounds a fairly small vaginal orifice. One of the indicators we look at closely is the size of the vaginal orifice. We measure it both horizontally and vertically. For many years it was understood that any prepubertal girl who had a vaginal opening greater than 4 mm had been sexually abused.<sup>1</sup> Since that time, however, it has been recognized that this 4-mm limit is not correct. Depending on the child's age, vaginal openings can go up to 6, 7, or 8 mm, especially in the older girls before they reach puberty. It is important to understand that the size of the vaginal opening is only one part of the examination.

It is also important to look at the appearance of the hymen. Is there a hymen, or has it been completely rubbed away, leaving just a thin rim of rough-edged tissue surrounding the vaginal orifice?

Is there generous hymenal tissue with an irregular notched border? Is there evidence of a healed transection of the hymenal ring? What is the appearance of the posterior fourchette? These additional findings are important

to look at in addition to the size of the vaginal opening. When puberty occurs, there is a concomitant estrogen effect. The hymenal tissue becomes thick, fluted, and succulent, and tends to overlap on itself. The posterior fourchette in prepubertal girls is a smooth, coved depression just below the inferior attachment of the hymenal tissue. In pubertal girls, this depression is longer, more narrow, and glandular with a cobblestone appearance. The posterior fourchette has an organized vascular pattern that is disrupted with the scarring caused by chronic abuse.

In my experience when I try to do an examination on teenage girls, they are quite nervous and uncomfortable. When this patient was seen, she was slumped over in her wheelchair. I explained to her what we were going to do and why we were going to do it. I said that we needed to check all parts of her body as part of her total checkup. She was very agreeable to that, and much to my surprise she allowed the examination without a twitch. She easily flexed her legs widely, and with any kind of stimulation of her inner thighs or touching of her genital area, there was no voluntary or involuntary reaction. This response seemed unusual because, again, with most young girls I have examined, regardless of whether they have been abused, it seems that any kind of touching of the genital area causes an involuntary reaction of the patient. I was able to insert a finger deep into her vagina and move her cervix without any difficulty. Her lack of response alarmed me because it was totally unlike any reaction I had seen in other teenage girls who come in for an examination. If I had anticipated her compliance, I would have been prepared to do a full pelvic examination including a colposcopic examination, which is now standard in alleged sexual abuse. I did not have the proper equipment available at the time of this examination. I did take a culture of her vagina for gonorrhea and a fluorescent antibody test for *Chlamydia*. She did have a positive standard vaginal culture for *Gardnerella vaginalis*. It was suggested that she have a follow-up speculum examination for visualization of the cervix and to obtain cervical cultures for *Chlamydia* and gonorrhea, since that type of examination is more reliable in postpubertal females.

DR GOLDBERG: She did return for a follow-up examination, which was less remarkable. She asked questions that were more typical of a 13-year-old, and she was a little hesitant initially. There was, however, no difficulty in performing the pelvic examination, placing the speculum, or obtaining the cultures. A colposcope was not available but is useful in examinations of suspected child abuse. A handheld magnifying glass may be used with similar effect.

DR DOUGLAS LANGROCK (*Second-Year Resident in Family Medicine*): You mentioned that there is some



**Brief Summary:**

**Contraindications:** Patients who have had allergic reactions to NAPROSYN, ANAPROX or ANAPROX DS or in whom aspirin or other NSAIDs induce the syndrome of asthma, rhinitis, and nasal polyps. Because anaphylactic reactions usually occur in patients with a history of such reactions, question patients for asthma, nasal polyps, urticaria, and hypotension associated with NSAIDs before starting therapy. If such symptoms occur, discontinue the drug. **Warnings:** Serious GI toxicity such as bleeding, ulceration, and perforation, can occur at any time, with or without warning symptoms, in patients treated chronically with NSAIDs. Remain alert for ulceration and bleeding in such patients even in the absence of previous GI tract symptoms. In clinical trials, symptomatic upper GI ulcers, gross bleeding or perforation appear to occur in approximately 1% of patients treated for 3-6 months, and in about 2-4% of patients treated for one year. Inform patients about the signs and/or symptoms of serious GI toxicity and what steps to take if they occur. Studies have not identified any subset of patients not at risk of developing peptic ulceration and bleeding. Except for a prior history of serious GI events and other risk factors known to be associated with peptic ulcer disease, such as alcoholism, smoking, etc., no risk factors (e.g., age, sex) have been associated with increased risk. Elderly or debilitated patients seem to tolerate ulceration or bleeding less and in the elderly, the most spontaneous reports of fatal GI events are in this population. In considering the use of relatively large doses (within the recommended dosage range), sufficient benefit should be anticipated to offset the potential increased risk of GI toxicity. **Precautions:** DO NOT GIVE NAPROSYN® (NAPROXEN) CONCOMITANTLY WITH ANAPROX® (NAPROXEN SODIUM) OR ANAPROX® DS (NAPROXEN SODIUM) SINCE THEY CIRCULATE IN PLASMA AS THE NAPROXEN ANION. Acute interstitial nephritis with hematuria, proteinuria, and nephrotic syndrome has been reported. Patients with impaired renal function, heart failure, liver dysfunction, patients taking diuretics, and the elderly are at greater risk of overt renal decompensation. If this occurs, discontinue the drug. Use with caution and monitor serum creatinine and/or creatinine clearance in patients with significantly impaired renal function. Use caution in patients with baseline creatinine clearance less than 20 mL/minute. Use the lowest effective doses in the elderly or in patients with chronic alcoholic liver disease or cirrhosis. With NSAIDs, borderline elevations of liver tests may occur in up to 15% of patients. They may progress, remain unchanged, or be transient with continued therapy. Elevations of SGPT or SGOT occurred in controlled clinical trials in less than 1% of patients. Severe hepatic reactions, including jaundice and fatal hepatitis, have been reported rarely. If liver disease develops or if systemic manifestations occur (e.g., eosinophilia or rash), discontinue therapy. If steroid dosage is reduced or eliminated during therapy, do so slowly and observe patients closely for adverse effects, including adrenal insufficiency and exacerbation of arthritis symptoms. Determine hemoglobin values periodically for patients with initial values of 10 grams or less who receive long-term therapy. Peripheral edema has been reported. Therefore, use with caution in patients with fluid retention, hypertension or heart failure. The drug's antipyretic and anti-inflammatory activities may reduce fever and inflammation, diminishing their diagnostic value. Conduct ophthalmic studies if any change or disturbance in vision occurs. For patients with restricted sodium intake, note that the suspension contains 8 mg/mL of sodium. **Information for Patients:** Side effects of NSAIDs can cause discomfort and, rarely, there are more serious side effects, such as GI bleeding, which may result in hospitalization and even fatal outcomes. Physicians may wish to discuss with patients the potential risks and likely benefits of NSAID treatment, particularly when they are used for less serious conditions where treatment without NSAIDs may be an acceptable alternative. Patients should use caution for activities requiring alertness if they experience drowsiness, dizziness, vertigo or depression during therapy. **Laboratory Tests:** Because serious GI tract ulceration and bleeding can occur without warning symptoms, follow chronically treated patients for signs and symptoms of these and inform them of the importance of this follow-up. **Drug Interactions:** Use caution when giving concomitantly with coumarin-type anticoagulants; a hydantoin, sulfonamide or sulfonylurea; furosemide; lithium; beta-blockers; probenecid; or methotrexate. **Drug/Laboratory Test Interactions:** The drug may decrease platelet aggregation and prolong bleeding time or increase urinary values for 17-ketogenic steroids. Temporarily stop therapy for 72 hours before doing adrenal function tests. The drug may interfere with urinary assays for G6HAA. **Carcinogenesis:** A 2-year rat study showed no evidence of carcinogenicity. **Pregnancy:** Category B. Do not use during pregnancy unless clearly needed. Avoid use during late pregnancy. **Nursing Mothers:** Avoid use in nursing mothers. **Pediatric Use:** Single doses of 2.5-5 mg/kg, with total daily dose not exceeding 15 mg/kg/day, are safe in children over 2 years of age. **Adverse Reactions:** In a study, GI reactions were more frequent and severe in rheumatoid arthritis patients on 1,500 mg/day than in those on 750 mg/day. In studies in children with juvenile arthritis, rash and prolonged bleeding times were more frequent, GI and CNS reactions about the same, and other reactions less frequent than in adults. Incidence Greater Than 1%: Probable Causal Relationship: GI: The most frequent complaints related to the GI tract: constipation; heartburn; abdominal pain; nausea; dyspepsia, diarrhoea, stomatitis. CNS: headache; dizziness; drowsiness; light-headedness; vertigo. Dermatologic: itching (pruritus); skin eruptions; ecchymoses; sweating, purpura. Special Senses: tinnitus; hearing disturbances, visual disturbances. Cardiovascular: edema; dyspnea; palpitations. General: thirst. Incidence Less Than 1%: Probable Causal Relationship: GI: abnormal liver function tests, GI bleeding and/or perforation, hematemesis, jaundice, melena, peptic ulceration with bleeding and/or perforation, vomiting. Renal: glomerular nephritis, hematuria, interstitial nephritis, nephrotic syndrome, renal disease. Hematologic: agranulocytosis, eosinophilia, granulocytopenia, leukopenia, thrombocytopenia. CNS: depression, dream abnormalities, inability to concentrate, insomnia, malaise, myalgia and muscle weakness. Dermatologic: alopecia, photosensitive dermatitis, skin rashes. Special Senses: hearing impairment. Cardiovascular: congestive heart failure. Respiratory: eosinophilic pneumonitis. General: anaphylactoid reactions, menstrual disorders, pyrexia (chills and fever). Causal Relationship Unknown: Hematologic: aplastic anemia, hemolytic anemia. CNS: cognitive dysfunction. Dermatologic: epidermal necrolysis, erythema multiforme, Stevens-Johnson syndrome, urticaria. GI: non-peptic GI ulceration, ulcerative stomatitis. Cardiovascular: vasculitis. General: angioneurotic edema, hyperglycemia, hypoglycemia. **Overdosage:** May have drowsiness, heartburn, indigestion, nausea, vomiting. Empty stomach. General supportive measures. In animals 0.5 g/kg of activated charcoal reduced plasma levels of naproxen. **Caution:** Federal law prohibits dispensing without prescription. See package insert for full Prescribing Information.

Continued on page 528

and acquaintances of their teenage daughters. Determination of sexual activity was entirely through self-report.

**DR GOLDBERG:** The authors stated that for any positive results, they reexamined and retook a history specifically requesting whether the subject was sexually active. None of the subjects on questioning changed her history.

**DR STEINBERG:** I think we all have questions about the reliability of self-reported sexual activity. It seems clear, however, that one cannot use the presence of *Gardnerella vaginalis* as an absolute marker of sexual activity. In this patient, the presence of *G vaginalis* is little more than an additional suggestion of sexual activity, especially in the context of historical factors and her clinical presentation.

**DR WALL:** Is there a possibility that the different reactions to the pelvic examination were due to the sex differences of the examiners? I am also curious about the family's reaction to the psychiatry referral.

**DR GOLDBERG:** Sex differences could certainly have accounted for the different reactions of this patient. The patient's father consistently refused or was otherwise unable to recognize possible psychological reasons for his daughter's illness. He reluctantly accepted our recommendation that his daughter undergo a psychiatric evaluation.

**DR HOLLADAY:** We clearly stated to the family that we also were very concerned about the patient's symptoms even though we did not completely understand them. We thought, but did not immediately state to the parents, that much of the history was quite suggestive of sexual abuse. There was a reliable letter and some very unusual sleeping arrangements. There are some dynamics in the parents' histories that were suggestive of some problems. The mother was from an alcoholic family, and we know that she was making a lot of excuses for her husband in the history that we had obtained. The father had his own difficulties. There was much denial of family problems. We did get a history of alcoholism, which is often found in families who have sexual abuse problems.

**DR GOLDBERG:** In our contact with CSD, the history of the patient's early morning prolonged grooming and the observations by Dr Steinberg and the team of lax pelvic tone as well as absent affect strongly suggested the possibility of pedophile activity. An aunt had notified CSD of her concerns about possible abuse and supplied the history of the patient's father abusing his two sisters. The aunt also reported specifically asking this child whether her father had been molesting her, and the child denied it. Another relative, who happened to be a CSD employee, also had reported concern about abuse of this patient. Because of the denial by the patient, however, the family was not further evaluated by CSD. There was also a history of violent and explosive behavior of the father

\* Incidence of reported reaction 3%-9%. Where unmarked, incidence less than 3%.



husband in the history that we had obtained. The father had his own difficulties. There was much denial of family problems. We did get a history of alcoholism, which is often found in families who have sexual abuse problems.

DR GOLDBERG: In our contact with CSD, the history of the patient's early morning prolonged grooming and the observations by Dr Steinberg and the team of lax pelvic tone as well as absent affect strongly suggested the possibility of pedophile activity. An aunt had notified CSD of her concerns about possible abuse and supplied the history of the patient's father abusing his two sisters. The aunt also reported specifically asking this child whether her father had been molesting her, and the child denied it. Another relative, who happened to be a CSD employee, also had reported concern about abuse of this patient. Because of the denial by the patient, however, the family was not further evaluated by CSD. There was also a history of violent and explosive behavior of the father involving law enforcement officers including the sheriff's deputy. CSD was notified several times by multiple health care providers but felt there was insufficient evidence to warrant their intervention.

DR WALL: It's very difficult for many medical professionals to deal with issues of child abuse directly. I am wondering how you addressed this issue with the patient and the family.

DR STEINBERG: I asked them directly.

## FOLLOW-UP AND DIAGNOSTIC CRITERIA

DR GOLDBERG: The team's recommendations on discharge were that the child return to school as soon as possible and that the family undergo counseling arranged through CSD. In fact, the patient was discharged from our institution directly to CSD to make those arrangements.

DR COMMERCOR: The patient was told she had a conversion disorder that was related to or caused by stress. She denied being under stress and was very upset at that diagnosis. The father was told the same thing.

DR GOLDBERG: What was her diagnosis from child psychiatry?

DR HOLLADAY: Undifferentiated somatiform disorder.

DR WILLIAM TOFFLER (*Assistant Professor, Department of Family Medicine*): Had the decision been made to investigate this further, what would be done?

CHILDREN'S SERVICES DIVISION (CSD) OFFICIAL: In our county, we would have made the report to the sheriff's office, and the deputy sheriff would have gone out with a protective services worker. Typically, we

would have tried to arrange a structured interview with the child away from the parents.

In juvenile court, conviction for child sexual abuse is determined by a preponderance of the evidence suggesting abuse has occurred and identifying the perpetrator. If abuse has been found to occur, but the perpetrator has not been conclusively identified, the judge would have to decide whether the child could remain in the family.

BECKY MERRITT (*Social Worker, Department of Family Medicine*): Has the father been known to law enforcement agencies prior to this time?

CSD OFFICIAL: Yes, there have been a lot of problems with the father. I have experienced very explosive, violent behavior in the contact I have had with him. He is a dangerous individual who is very intimidating.

After the patient's evaluation, we felt that the best strategy was to try to help this family deal with their many problems. They were referred to two private family therapists, and reluctantly agreed to follow through with these referrals.

DR WALL: Can you summarize what happened when the girl was discharged?

DR GOLDBERG: This case illustrates many of the difficulties in management of suspected child and adolescent sexual abuse. For a diagnosis to be established, overt physical evidence, or disclosure by the abused, or admission by the perpetrator must be present. *Sexual abuse* is defined as the involvement of children and adolescents in sexual activities they do not understand on the basis of their developmental level, to which they cannot give consent, or that violate the social taboos of family or society.<sup>3</sup> In the event that a diagnosis cannot be definitively established, the appropriate course of action will depend on the circumstances of the case.

Following discharge, the family reported to Children's Services Division of their county and began interviews with a family therapist. During this time the parents took the child for further medical evaluation. The father obtained access to records that commented on the confidential letter revealing a purported history of multiple sexual abuses by the father. The father then became physically threatening to the family. Armed, he disrupted the house and reportedly threatened to kill his entire family and himself. Because of these occurrences, the children were taken into custody, and at a shelter hearing, the judge ruled there was reasonable cause to keep the children in care until wardship could be determined.

While in foster care, the patient reportedly improved her school attendance and social behavior, and her somatic complaints diminished. These symptoms recurred only after contact with the father and during a subsequent hearing. Although there were many other suspicious events and behaviors by the father, he passed a two-

Continued on page 532



## TAGAMET® (brand of cimetidine)

See complete prescribing information in SK&F LAB CO. literature or PDR. The following is a brief summary.

**Contraindications:** Tagamet® is contraindicated for patients known to have hypersensitivity to the product.

**Precautions:** Rare instances of cardiac arrhythmias and hypotension have been reported following the rapid administration of Tagamet® (brand of cimetidine hydrochloride) injection by intravenous bolus.

Symptomatic response to Tagamet® therapy does not preclude the presence of a gastric malignancy. There have been rare reports of transient healing of gastric ulcers despite subsequently documented malignancy.

Reversible confusional states have been observed on occasion, predominantly in severely ill patients.

Tagamet® has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, phenytoin, propranolol, chlorthalidone, diazepam, certain tricyclic antidepressants, lidocaine, theophylline and metronidazole. Clinically significant effects have been reported with the warfarin anticoagulants; therefore, close monitoring of prothrombin time is recommended, and adjustment of the anticoagulant dose may be necessary when Tagamet® is administered concomitantly. Interaction with phenytoin, lidocaine and theophylline has also been reported to produce adverse clinical effects.

However, a crossover study in healthy subjects receiving either Tagamet® 300 mg q.i.d. or 800 mg h.s. concomitantly with a 300 mg b.i.d. dosage of theophylline (Theo-Dur®, Key Pharmaceuticals, Inc.) demonstrated less alteration in steady-state theophylline peak serum levels with the 800 mg h.s. regimen, particularly in subjects aged 54 years and older. Data beyond ten days are not available. [Note: All patients receiving theophylline should be monitored appropriately, regardless of concomitant drug therapy.]

In a 24-month toxicity study in rats, at dose levels approximately 8 to 48 times the recommended human dose, benign Leydig cell tumors were seen. These were common in both the treated and control groups, and the incidence became significantly higher only in the aged rats receiving Tagamet®.

A weak antiandrogenic effect has been demonstrated in animals. In human studies, Tagamet® has been shown to have no effect on spermatogenesis, sperm count, motility, morphology or in vitro fertilizing capacity. Pregnancy Category B: Reproduction studies have been performed in rats, rabbits and mice at doses up to 40 times the normal human dose and have revealed no evidence of impaired fertility or harm to the fetus due to Tagamet®. There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproductive studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.

Lack of experience to date precludes recommending Tagamet® for use in children under 16 unless anticipated benefits outweigh potential risks; generally, nursing should not be undertaken by patients taking the drug since cimetidine is secreted in human milk.

**Adverse Reactions:** Diarrhea, dizziness, somnolence, headache. Reversible confusional states [e.g., mental confusion, agitation, psychosis, depression, anxiety, hallucinations, disorientation], predominantly in severely ill patients, have been reported. Reversible impotence in patients with pathological hypersecretory disorders receiving Tagamet®, particularly in high doses for at least 12 months, has been reported. The incidence of impotence in large-scale surveillance studies at regular doses has not exceeded that commonly reported in the general population. Gynecomastia has been reported in patients treated for one month or longer. Decreased white blood cell counts in Tagamet®-treated patients (approximately 1 per 100,000 patients), including agranulocytosis (approximately 3 per million patients), have been reported, including a few reports of recurrence on rechallenge. Most of these reports were in patients who had serious concomitant illnesses and received drugs and/or treatment known to produce neutropenia. Thrombocytopenia (approximately 3 per million patients) and, very rarely, cases of aplastic anemia have also been reported. Increased serum transaminase has been reported. Reversible adverse hepatic effects, cholestatic or mixed cholestatic-hepatocellular in nature, have been reported rarely. Because of the predominance of cholestatic features, severe parenchymal injury is considered highly unlikely. A single case of biopsy-proven periportal hepatic fibrosis in a patient receiving Tagamet® has been reported. Increased plasma creatinine has been reported. Rare cases of fever, interstitial nephritis, urinary retention, pancreatitis and allergic reactions, including anaphylaxis and hypersensitivity vasculitis, have been reported. Rare cases of bradycardia, tachycardia and A-V heart block have been reported with H<sub>2</sub>-receptor antagonists. Reversible arthralgia, myalgia and exacerbation of joint symptoms in patients with preexisting arthritis have been reported rarely. Rare cases of polymyositis have been reported, but no causal relationship has been established. Mild rash and, very rarely, cases of severe generalized skin reactions [e.g., Stevens-Johnson syndrome, epidermal necrolysis, erythema multiforme, exfoliative dermatitis and generalized exfoliative erythroderma] have been reported with H<sub>2</sub>-receptor antagonists. Reversible alopecia has been reported very rarely.

**How Supplied: Tablets:** 200 mg tablets in bottles of 100; 300 mg tablets in bottles of 100 and Single Unit Packages of 100 (intended for institutional use only); 400 mg tablets in bottles of 60 and Single Unit Packages of 100 (intended for institutional use only); and 800 mg Tiltab® tablets in bottles of 30 and Single Unit Packages of 100 (intended for institutional use only).

**Liquid:** 300 mg/5 mL, in 8 fl oz (237 mL) amber glass bottles and in single-dose units (300 mg/5 mL), in packages of 10 (intended for institutional use only).

**Injection:**  
**Vials:** 300 mg/2 mL in single-dose vials, in packages of 10 and 30, and in 8 mL multiple-dose vials, in packages of 10 and 25.

**Prefilled Syringes:** 300 mg/2 mL in single-dose prefilled disposable syringes.

**Single-Dose Premixed Plastic Containers:** 300 mg in 50 mL of 0.9% Sodium Chloride in single-dose plastic containers, in packages of 4 units. No preservative has been added.

Exposure of the premixed product to excessive heat should be avoided. It is recommended the product be stored at controlled room temperature. Brief exposure up to 40°C does not adversely affect the premixed product.

**ADD-Vantage® Vials:** 300 mg/2 mL in single-dose ADD-Vantage® Vials, in packages of 25.

Tagamet® (brand of cimetidine hydrochloride) injection premixed in single-dose plastic containers is manufactured for SK&F Lab Co. by Baxter Healthcare Corporation, Deerfield, IL 60015.

BRS-TG:L79B

Date of issuance Apr. 1989

## SK&F LAB CO.,

Cidra, P.R. 00639

© SK&F Lab Co., 1989

## CHILD SEXUAL ABUSE

Continued from page 530

question polygraph, and at a later hearing, the children were returned to the family.

The child's failure to disclose information and her continued denial that anything had happened is not unusual. When neglect, prolonged abuse, or violence is involved, children do not usually disclose the events unless they perceive themselves as safe from the perpetrator.

The management of suspected sexual abuse is dictated by the particular social situation. Often the mother is torn between the alleged perpetrator and the child. Family crisis and disruption may occur. Stages of reaction may include grief-like responses of shock, disbelief, anger, bargaining, and acceptance.<sup>4</sup> The physician may well become the object of the family's anger. Prolonged psychotherapy is helpful, and disclosure need not be made to initiate therapy. Therapy may be individual or group. Family assessment is also important, but family therapy, if the perpetrator is a family member, may be contraindicated.

In all states, suspected child sexual abuse must be reported to a designated authority. The reporting physician is protected from prosecution, and only suspicion of abuse is required to warrant notification. Determination of guilt is a decision reached only in the court system.<sup>5</sup>

## References

1. Cantwell HB: Update on vaginal inspection as it relates to child sexual abuse in girls under thirteen. *Child Abuse Negl* 1987; 11:545-546
2. Bump RC, Buesching WJ III: Bacterial vaginosis in virginal and sexually active adolescent females. Evidence against exclusive sexual transmission. *Am J Obstet Gynecol* 1988; 158:935-939
3. Schecter MD, Reberge L: Sexual exploitation. In Helfer RE, Kempe CH (eds): *Child Abuse and Neglect: The Family and Community*. Cambridge, Mass, Ballinger Publishing, 1976
4. Berkowitz CD: Sexual abuse of children and adolescents. *Adv Pediatr* 1987; 34:275-312
5. Morris JL: To report or not to report. Physicians' attitudes toward discipline and child abuse. *Am J Dis Child* 1985; 139:194-197